QureMed – Long Acting Relief for the Toughest Migraines

We are developing a minimally invasive treatment for people whose migraines don't respond to standard medications.

Learn More For Physicians Contact Us

The Patients We Serve

When migraine becomes a way of life

Most people think of migraine as an occasional bad headache. For the patients we focus on, migraine is almost a full-time job—headache on 15 or more days a month despite trying all the usual drugs. That's chronic, refractory, disabling migraine. These patients can't reliably work, parent, or live day-to-day.

Some also suffer status migrainosus—a migraine attack that simply doesn't switch off. It's like a pain alarm stuck in the “on” position for days, even after emergency-room visits and IV medications.

These are the patients the current system has run out of answers for. QureMed exists to change that.

QureMed's therapy is investigational and not yet approved for routine clinical use.

15+ Headache days per month
24-72 hrs Status migrainosus episodes
Chronic Refractory, disabling migraine
ER visits Even IV meds don't help

Our Approach

A new way to calm migraine pain at its source

QureMed is developing a procedure-based, minimally invasive therapy delivered through the blood vessels of the head. The goal is simple:

  • Act directly on the pain pathways that drive the worst migraine attacks
  • Provide relief that lasts far beyond a single infusion or injection
  • Fit into workflows that interventional specialists already use today

Our work builds on a decade of experience showing that targeted, catheter-based approaches can help shut down otherwise untreatable headache attacks. QureMed's mission is to translate that insight into a standardized, long-acting treatment option for the sickest migraine patients.

Targeted Direct action on pain pathways
Long-Acting Relief beyond single infusions
Minimally Invasive Catheter-based delivery
Standardized Treatment for the sickest patients

Evidence So Far

A concept with growing clinical momentum

Over the past several years:

  • Case reports and series have shown that targeted intra-arterial treatments can rapidly relieve intractable headaches and status migrainosus when standard medications fail.
  • The approach has been extended to other severe headache and pain conditions, strengthening the link between specific cranial vessels and headache pathways.
  • Independent groups have initiated formal clinical studies using catheter-based interventions for migraine and related disorders.

QureMed is building on this foundation with a structured preclinical and clinical development program.

Case Studies Documented rapid relief results
Growing Evidence Extended to multiple conditions
Clinical Studies Independent research underway
QureMed Program Structured development path

Adoption & Value

Designed to integrate, not disrupt

Because our therapy is delivered through the vasculature, it is intended to:

  • Build on procedures interventionalists already perform, rather than introduce unfamiliar techniques
  • Be used in collaboration with headache specialists and pain teams who manage these complex patients

For hospitals and payers, the potential value lies in:

  • Fewer emergency-room visits and unplanned admissions
  • Reduced use of rescue infusions and procedures
  • Less reliance on opioids and other systemic medications
  • Better quality of life for a small but very high-cost patient population
Seamless Fit Builds on existing procedures
Collaborative Works with specialist teams
Fewer ER Visits Reduced unplanned admissions
Better Outcomes Improved quality of life

Development Status

Where we are

QureMed's migraine program is currently in preclinical and regulatory planning, with future steps that include:

Safety & Feasibility Studies

Early Clinical Trials

In carefully selected patients

Larger Studies

To measure impact on healthcare utilization and patient outcomes

All QureMed therapies are in development and are not yet commercially available.

Founders

Built by physicians and builders who live in this space

Adnan I. Qureshi, MD

Adnan I. Qureshi, MD

An internationally recognized stroke neurologist and neurointerventional researcher, a professor who has led major stroke programs and trials that helped shape AHA and ASA guidelines.

Fareed Suri, MD

Fareed Suri, MD

A neuro-intervention-focused clinician and builder, driving product design and execution.

Ameer E. Hassan, DO

Ameer E. Hassan, DO

Triple board-certified in neurology, vascular neurology, and neuroendovascular surgery. He leads the Neuroscience Department at Valley Baptist Medical Center, is a professor at UT Rio Grande Valley, and is the immediate past president of the Society of Vascular and Interventional Neurology, connecting us to interventionalists worldwide.

For Physicians, Collaborators & Partners

If you are interested in learning more about QureMed's migraine program or exploring collaboration:

info@quremedrx.com Contact Form

Contact Us

Get in touch with the QureMed team

info@quremedrx.com